Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 22:11:589531.
doi: 10.3389/fimmu.2020.589531. eCollection 2020.

Pathological Role of Unsaturated Aldehyde Acrolein in Diabetic Retinopathy

Affiliations
Review

Pathological Role of Unsaturated Aldehyde Acrolein in Diabetic Retinopathy

Miyuki Murata et al. Front Immunol. .

Abstract

With increasing prevalence of diabetes and a progressively aging society, diabetic retinopathy is emerging as one of the global leading causes of blindness. Recent studies have shown that vascular endothelial growth factor (VEGF) plays a central role in the pathogenesis of diabetic retinopathy and anti-VEGF agents have become the first-line therapy for the vision-threatening disease. However, recent studies have also demonstrated that diabetic retinopathy is a multifactorial disease and that VEGF-independent mechanism(s) also underlie much of the pathological changes in diabetic retinopathy. Acrolein is a highly reactive unsaturated aldehyde and is implicated in protein dysfunction. As acrolein is common in air pollutants, previous studies have focused on it as an exogenous causative factor, for instance, in the development of respiratory diseases. However, it has been discovered that acrolein is also endogenously produced and induces cell toxicity and oxidative stress in the body. In addition, accumulating evidence suggests that acrolein and/or acrolein-conjugated proteins are associated with the molecular mechanisms in diabetic retinopathy. This review summarizes the pathological roles and mechanisms of endogenous acrolein production in the pathogenesis of diabetic retinopathy.

Keywords: acrolein; diabetic retinopathy; inflammation; oxidative stress; spermine oxidase; vascular adhesion protein-1.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of (A) acrolein and (B) one of the major acrolein-conjugated proteins, Nϵ-(3-formyl-3, 4-dehydropiperidino) lysine adduct (FDP-Lys).
Figure 2
Figure 2
Enzymatic oxidation of spermine mediated by vascular adhesion protein-1 (VAP-1) function as semicarbazide-sensitive amine oxidase (SSAO). VAP-1 converts spermine to acrolein and hydrogen peroxide, both of which increase oxidative stress in the body.
Figure 3
Figure 3
Sequential steps of release of the soluble form of VAP-1 from retinal capillary endothelial cells. (A) VAP-1 and other leukocyte adhesion molecules facilitate leukocyte recruitment upon inflammation. (B) Recruited leukocytes secrete inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β(IL-1β) and vascular endothelial cell growth factor (VEGF). (C) MMP-2 and MMP-9 induced by the inflammatory cytokines proteolytically cleave the VAP-1 protein. (D) Soluble form of VAP-1 was released from the surface of endothelial cells.
Figure 4
Figure 4
A schematic of oxidative degradation of spermine by spermine oxidase (SMOX). SMOX catalyzes spermine and produces spermidine, hydrogen peroxides, and 3-aminopropanal, which is non-enzymatically converted to acrolein.
Figure 5
Figure 5
A schematic summary illustrating the role of acrolein in diabetic retinopathy.

References

    1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetes Med (1997) 14 Suppl 5:S1–85. 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO;2-I - DOI - PubMed
    1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract (2019) 157:107843. 10.1016/j.diabres.2019.107843 - DOI - PubMed
    1. Negi A, Vernon SA. An overview of the eye in diabetes. J R Soc Med (2003) 96(6):266–72. 10.1258/jrsm.96.6.266 - DOI - PMC - PubMed
    1. Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol (1994) 118(4):445–50. 10.1016/s0002-9394(14)75794-0 - DOI - PubMed
    1. Lebherz C, Maguire AM, Auricchio A, Tang W, Aleman TS, Wei Z, et al. Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. Diabetes (2005) 54(4):1141–9. 10.2337/diabetes.54.4.1141 - DOI - PubMed

Publication types